RAD-140 Testolone SARM Guide: Research, Uses and Cycle Information

RAD-140, Testolone and vosilasarm are names used for the same investigational selective androgen receptor modulator. The compound has been evaluated in preclinical research involving muscle, bone and androgen-receptor activity, followed by a small first-in-human study in women with advanced breast cancer.

What Is RAD-140 Testolone?

RAD-140 is a nonsteroidal selective androgen receptor modulator, commonly abbreviated as a SARM. Testolone is the name most frequently used within the performance market, while vosilasarm is the recognized nonproprietary name associated with the compound.

RAD-140 was originally developed for research involving conditions such as muscle loss, declining physical function and bone health. Its later clinical development focused on androgen-receptor-positive breast cancer.

It remains an investigational compound and has not been approved as a general muscle-building, cutting or athletic-performance medicine.

How Does RAD-140 Work?

RAD-140 binds to and activates the androgen receptor. Androgen receptors influence muscle, bone and numerous other tissues throughout the body.

The objective behind SARM development was to investigate whether compounds could produce different levels of androgen-receptor activity across different tissues. Selective does not mean that RAD-140 acts only in muscle or that hormonal and systemic effects elsewhere are impossible.

Early laboratory research described RAD-140 as a potent and orally active androgen-receptor modulator with tissue-dependent activity in experimental models.

Preclinical RAD-140 Research

The original published RAD-140 research involved laboratory, rodent and primate models rather than bodybuilding trials in humans.

In animal research, RAD-140 demonstrated androgen-receptor activity in muscle and bone measurements. Researchers also observed different activity patterns in prostate and seminal-vesicle tissue compared with muscle tissue.

These results helped establish RAD-140 as a selective androgen receptor modulator, but animal findings cannot be used to predict a specific amount of muscle growth, strength improvement or fat reduction in humans.

Human Research on RAD-140

The first published human study of RAD-140 was a phase 1 dose-escalation trial involving 22 postmenopausal women with estrogen-receptor-positive and HER2-negative metastatic breast cancer.

Participants received once-daily RAD-140 amounts of 50 mg, 100 mg or 150 mg under clinical supervision. The researchers evaluated safety, tolerability, pharmacokinetics, androgen-receptor engagement and preliminary antitumor activity.

The recommended dose for further research was reported as 100 mg once daily. The study found evidence that RAD-140 engaged the androgen receptor and reported preliminary antitumor activity in that specific cancer population.

This study did not evaluate healthy men, bodybuilding cycles, muscle growth, fat loss, strength or athletic performance. Its results should not be presented as proof of recreational RAD-140 outcomes.

What the Human Study Does and Does Not Show

The phase 1 trial confirms that RAD-140 has been administered to humans and that measurable androgen-receptor activity occurred.

However, the participants, research objective and amounts used were completely different from common performance-market use. The study involved women with advanced cancer receiving specialist medical monitoring.

There is currently no comparable placebo-controlled human trial showing how RAD-140 affects muscle mass, strength or body composition in healthy recreational users.

Why RAD-140 Is Discussed for Lean Mass

RAD-140 became popular within the SARM market because early preclinical research showed anabolic activity in muscle-related experimental models.

This led to widespread discussion of Testolone for lean mass, bulking and body recomposition. Those uses are based primarily on preclinical findings and non-medical experience rather than controlled bodybuilding studies.

Training, nutrition, calorie intake, previous experience and individual response remain important influences on any change in body composition.

RAD-140 and Cutting Discussions

RAD-140 is also commonly discussed during cutting phases because users may want to preserve lean tissue while reducing calorie intake.

RAD-140 should not be described as a direct fat-burning compound. Published research has not established that it independently causes fat loss in healthy people.

Any reduction in body fat remains strongly influenced by total calorie intake, diet adherence, activity and training.

Common RAD-140 Cycle Discussions

Online SARM communities commonly discuss RAD-140 cycles lasting approximately six to eight weeks, with daily amounts often discussed in the 5–20 mg range.

These are community use patterns rather than clinically validated protocols. The available human study used much higher amounts for a completely different medical research purpose and cannot be used to validate bodybuilding-cycle recommendations.

Higher amounts should not automatically be assumed to produce proportionally greater muscle, strength or body-composition results.

Does RAD-140 Require PCT?

RAD-140 interacts with androgen receptors and may affect normal hormonal signalling. The degree of suppression and recovery may vary according to the amount used, cycle duration, previous exposure, additional compounds and individual hormone levels.

A short cycle should not automatically be treated as non-suppressive. Cycle length alone cannot reliably determine whether post-cycle support is appropriate.

Blood testing before and after a cycle provides more useful information than relying only on symptoms or automatically applying the same PCT plan after every cycle.

Available options can be compared in the SARM PCT and Post-Cycle Support category. Enclomiphene, Clomid, Nolvadex, Arimidex and HCG work through different mechanisms and should not be treated as interchangeable products.

RAD-140 Compared With LGD-4033

RAD-140 and LGD-4033 are both genuine selective androgen receptor modulators, but they are separate compounds with different research histories.

LGD-4033 Ligandrol has a published placebo-controlled study in healthy men that measured lean body mass and hormonal changes over 21 days.

RAD-140 has human research in metastatic breast cancer, but no equivalent controlled body-composition study in healthy men. Claims that RAD-140 is automatically stronger than LGD-4033 are therefore not established through direct comparative human trials.

RAD-140 Compared With Ostarine

RAD-140 and Ostarine both activate androgen receptors, but Ostarine has been evaluated in several controlled studies involving lean body mass and physical function.

Ostarine MK-2866 therefore has a broader human body-composition evidence base, while RAD-140 relies more heavily on preclinical research and its oncology development program.

The Sarms Thailand RAD-140 product contains 10 mg per ml, while the Ostarine product contains 25 mg per ml. Concentration alone does not determine which compound is stronger or more suitable.

RAD-140 in SARM Stacks

RAD-140 appears in several pre-built combinations, including packages positioned around cutting, lean mass and body recomposition.

Some of these stacks also contain LGD-4033, Ostarine, Cardarine or MK-677. Cardarine and MK-677 are commonly grouped with SARMs commercially but belong to different compound classes.

Combining several compounds creates a more complex cycle than using RAD-140 alone. Each product should be evaluated separately rather than treating the stack as one compound.

Current packages can be reviewed in the SARM Stacks in Thailand category.

RAD-140 Research Status

RAD-140 remains investigational. Published research includes preclinical androgen-receptor studies and a small first-in-human oncology trial, but no approved bodybuilding or athletic-performance indication.

RAD-140 is specifically listed as a prohibited selective androgen receptor modulator under the World Anti-Doping Agency Prohibited List. Athletes subject to anti-doping testing should avoid products containing RAD-140, Testolone, vosilasarm or EP0062.

Frequently Asked Questions

Are RAD-140, Testolone and Vosilasarm the same compound?

Yes. RAD-140 is the original development code, Testolone is the familiar market name and vosilasarm is the recognized nonproprietary name associated with the same substance.

Is RAD-140 a real SARM?

Yes. RAD-140 is a nonsteroidal selective androgen receptor modulator that activates the androgen receptor.

Has RAD-140 been studied in humans?

Yes. A small phase 1 study evaluated RAD-140 in postmenopausal women with metastatic breast cancer. It was not a muscle-building, cutting or athletic-performance study.

Has RAD-140 been proven to build muscle in healthy people?

No placebo-controlled human trial has established a specific muscle-building result for RAD-140 in healthy recreational users. Most muscle-related evidence comes from preclinical research.

How much RAD-140 is in 1 ml?

In a liquid containing 10 mg per ml, one full millilitre contains 10 mg of RAD-140.

What RAD-140 cycle length is commonly discussed?

Six-to-eight-week cycles are frequently discussed in non-medical SARM communities. This is an informal use pattern rather than a duration established through controlled clinical trials.

Does every RAD-140 cycle require PCT?

No single answer applies to every cycle. The amount, duration, other compounds used and individual hormonal response all matter. Relevant blood testing provides clearer information than cycle length alone.

RAD-140 Research Sources

• Discovery and preclinical characterization of RAD-140
• First-in-human phase 1 RAD-140 study
• National Cancer Institute RAD-140 clinical-trial record
• PubChem information for RAD-140 and vosilasarm
• World Anti-Doping Agency Prohibited List